EP4342995A2
(en)
|
2006-03-31 |
2024-03-27 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
EP2173379B2
(en)
|
2007-07-02 |
2023-07-05 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for treating and diagnosing cancer
|
EP3127921A1
(en)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
KR102269708B1
(ko)
|
2008-04-11 |
2021-06-25 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복 결합하는 항원 결합 분자
|
ES2788869T3
(es)
|
2009-09-03 |
2020-10-23 |
Merck Sharp & Dohme |
Anticuerpos anti-GITR
|
AU2011337704B2
(en)
|
2010-11-30 |
2017-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
CN103842383B
(zh)
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
多特异性fab融合蛋白及其使用方法
|
AU2012284254B2
(en)
|
2011-07-15 |
2015-07-09 |
Oncomed Pharmaceuticals, Inc. |
RSPO binding agents and uses thereof
|
US20130108641A1
(en)
*
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
KR101566538B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Th17 세포 전환용 에피토프 및 이의 용도
|
PE20150360A1
(es)
|
2012-07-13 |
2015-03-20 |
Oncomed Pharm Inc |
Agentes de union de proteina de r-espondina humana (rsp03) y usos de los mismos
|
TWI717591B
(zh)
|
2012-08-24 |
2021-02-01 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
US11236168B2
(en)
|
2012-08-24 |
2022-02-01 |
Chugai Seiyaku Kabushiki Kaisha |
Mouse FcγammaRII-specific Fc antibody
|
WO2014052545A2
(en)
|
2012-09-28 |
2014-04-03 |
Dana-Farber Cancer Institute, Inc. |
Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis
|
CN116637183A
(zh)
|
2012-12-03 |
2023-08-25 |
百时美施贵宝公司 |
强化免疫调变性Fc融合蛋白的抗癌活性
|
WO2015116178A1
(en)
*
|
2014-01-31 |
2015-08-06 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector t cells
|
US9834610B2
(en)
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
KR20210130260A
(ko)
|
2013-04-02 |
2021-10-29 |
추가이 세이야쿠 가부시키가이샤 |
Fc영역 개변체
|
KR102564207B1
(ko)
|
2013-08-08 |
2023-08-10 |
싸이튠 파마 |
Il―15 및 il―15r 알파 스시 도메인 기반 모듈로카인
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
JP6546178B2
(ja)
|
2013-09-13 |
2019-07-17 |
ジェネンテック, インコーポレイテッド |
細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
|
MY176026A
(en)
|
2013-09-13 |
2020-07-22 |
Genentech Inc |
Methods and composions comprising purified recombinant polypeptides
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
JP2016537345A
(ja)
|
2013-11-13 |
2016-12-01 |
ノバルティス アーゲー |
免疫応答を増強するためのmTOR阻害剤
|
EP3083964B1
(en)
|
2013-12-19 |
2022-01-26 |
Novartis AG |
Human mesothelin chimeric antigen receptors and uses thereof
|
NZ722326A
(en)
|
2013-12-24 |
2019-09-27 |
Bristol Myers Squibb Co |
Tricyclic compounds as anticancer agents
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
ES2862203T3
(es)
|
2014-03-24 |
2021-10-07 |
Novartis Ag |
Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
|
KR102487608B1
(ko)
|
2014-04-07 |
2023-01-12 |
노파르티스 아게 |
항-cd19 키메라 항원 수용체를 사용한 암의 치료
|
MA47849A
(fr)
|
2014-05-28 |
2020-01-29 |
Agenus Inc |
Anticorps anti-gitr et leurs procédés d'utilisation
|
WO2015188085A1
(en)
|
2014-06-06 |
2015-12-10 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
WO2015187835A2
(en)
|
2014-06-06 |
2015-12-10 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用cd33嵌合抗原受體治療癌症
|
CA2955386A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
EP3660042B1
(en)
|
2014-07-31 |
2023-01-11 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
EP3177593A1
(en)
|
2014-08-06 |
2017-06-14 |
Novartis AG |
Quinolone derivatives as antibacterials
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
US20170247437A1
(en)
*
|
2014-08-15 |
2017-08-31 |
Oncomed Pharmaceuticals, Inc. |
Rspo1 binding agents and uses thereof
|
CN112410363A
(zh)
|
2014-08-19 |
2021-02-26 |
诺华股份有限公司 |
抗cd123嵌合抗原受体(car)用于癌症治疗
|
EP3186274B1
(en)
|
2014-08-27 |
2021-10-06 |
Dana-Farber Cancer Institute, Inc. |
Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
|
US11344620B2
(en)
|
2014-09-13 |
2022-05-31 |
Novartis Ag |
Combination therapies
|
WO2016044295A1
(en)
|
2014-09-16 |
2016-03-24 |
Oncomed Pharmaceuticals, Inc. |
Treatment of fibrotic diseases
|
ES2891332T3
(es)
|
2014-09-17 |
2022-01-27 |
Novartis Ag |
Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
|
WO2016054638A1
(en)
*
|
2014-10-03 |
2016-04-07 |
Dana-Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
|
WO2016054555A2
(en)
|
2014-10-03 |
2016-04-07 |
Novartis Ag |
Combination therapies
|
MA41044A
(fr)
*
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
EP3204777A1
(en)
|
2014-10-08 |
2017-08-16 |
Novartis AG |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
AU2015333687B2
(en)
|
2014-10-14 |
2021-03-18 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to PD-L1 and uses thereof
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
UY36391A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
|
EA201790806A1
(ru)
|
2014-11-05 |
2017-11-30 |
Флексус Байосайенсиз, Инк. |
Иммунорегулирующие средства
|
CA2968382A1
(en)
|
2014-11-21 |
2016-05-26 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
MY189836A
(en)
|
2014-11-21 |
2022-03-11 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
SI3233843T1
(sl)
|
2014-12-16 |
2019-12-31 |
Novartis Ag |
Spojine izoksazol hidroksamične kisline kot LPXC inhibitorji
|
MA41294A
(fr)
|
2014-12-19 |
2017-11-08 |
Chugai Pharmaceutical Co Ltd |
Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
TW201630907A
(zh)
|
2014-12-22 |
2016-09-01 |
必治妥美雅史谷比公司 |
TGFβR拮抗劑
|
KR102644115B1
(ko)
|
2014-12-23 |
2024-03-05 |
브리스톨-마이어스 스큅 컴퍼니 |
Tigit에 대한 항체
|
US10273300B2
(en)
|
2014-12-29 |
2019-04-30 |
The Trustees Of The University Of Pennsylvania |
Methods of making chimeric antigen receptor-expressing cells
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
CN114773470A
(zh)
|
2015-02-05 |
2022-07-22 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
US9884868B2
(en)
|
2015-03-02 |
2018-02-06 |
Rigel Pharmaceuticals, Inc. |
TGF-beta inhibitors
|
SG11201706756VA
(en)
|
2015-03-10 |
2017-09-28 |
Aduro Biotech Inc |
Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
|
UY36601A
(es)
|
2015-04-03 |
2016-09-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Inhibidores de la función enzimática de la indolamina-2,3-dioxigenasa (ido) y composiciones farmacéuticas que los contienen
|
EP3280795B1
(en)
|
2015-04-07 |
2021-03-24 |
Novartis AG |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
HUE059218T2
(hu)
|
2015-04-08 |
2022-11-28 |
Novartis Ag |
CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
|
TW201642897A
(zh)
|
2015-04-08 |
2016-12-16 |
F 星生物科技有限公司 |
Her2結合劑治療
|
PL3283527T3
(pl)
|
2015-04-13 |
2021-06-14 |
Five Prime Therapeutics, Inc. |
Leczenie skojarzone nowotworów
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
ES2948133T3
(es)
|
2015-04-17 |
2023-08-31 |
Novartis Ag |
Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
|
LT3283107T
(lt)
|
2015-04-17 |
2020-09-10 |
Bristol-Myers Squibb Company |
Kompozicija apimanti ipilimumabo ir nivolumabo kombinaciją
|
US20180298068A1
(en)
|
2015-04-23 |
2018-10-18 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
US10683290B2
(en)
|
2015-05-11 |
2020-06-16 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
BR112017025297A2
(pt)
|
2015-06-03 |
2018-08-14 |
Bristol-Myers Squibb Company |
anticorpos anti-gitr para diagnóstico do câncer
|
US20190192565A1
(en)
*
|
2015-06-03 |
2019-06-27 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
|
BR112017028353A2
(pt)
|
2015-06-29 |
2018-09-04 |
The Rockfeller University |
anticorpos para cd40 com atividade agonista melhorada
|
WO2017009842A2
(en)
|
2015-07-16 |
2017-01-19 |
Biokine Therapeutics Ltd. |
Compositions and methods for treating cancer
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
CA2992298A1
(en)
|
2015-07-23 |
2017-01-26 |
Inhibrx Lp |
Multivalent and multispecific gitr-binding fusion proteins
|
EP3328861A1
(en)
|
2015-07-28 |
2018-06-06 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
CN108349976A
(zh)
|
2015-08-25 |
2018-07-31 |
百时美施贵宝公司 |
TGFβ受体拮抗剂
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
US11059899B1
(en)
|
2015-10-22 |
2021-07-13 |
Ablynx N.V. |
Polypeptides that bind glucocorticoid-induced TNFR family-related receptor (GITR)
|
TW201722985A
(zh)
|
2015-11-02 |
2017-07-01 |
戊瑞治療有限公司 |
Cd80胞外域多肽及其用於癌症治療
|
CN108697791B
(zh)
|
2015-11-03 |
2022-08-23 |
詹森生物科技公司 |
特异性结合pd-1的抗体及其用途
|
EA201891121A1
(ru)
|
2015-11-19 |
2018-12-28 |
Бристол-Майерс Сквибб Компани |
Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения
|
SG11201804134YA
(en)
|
2015-11-23 |
2018-06-28 |
Five Prime Therapeutics Inc |
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
US11447557B2
(en)
|
2015-12-02 |
2022-09-20 |
Agenus Inc. |
Antibodies and methods of use thereof
|
US10450318B2
(en)
|
2015-12-15 |
2019-10-22 |
Bristol-Myers Squibb Company |
CXCR4 receptor antagonists
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
JP2019506844A
(ja)
|
2015-12-18 |
2019-03-14 |
ノバルティス アーゲー |
CD32bを標的とする抗体およびその使用方法
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
JP7141336B2
(ja)
|
2015-12-25 |
2022-09-22 |
中外製薬株式会社 |
抗ミオスタチン抗体および使用方法
|
JP2019500874A
(ja)
|
2015-12-28 |
2019-01-17 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞の作製方法
|
IL260218B2
(en)
|
2016-01-11 |
2023-04-01 |
Novartis Ag |
Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
|
ES2897913T3
(es)
|
2016-02-19 |
2022-03-03 |
Novartis Ag |
Compuestos de piridona tetracíclicos como antivirales
|
SG11201807489PA
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
IL295230A
(en)
|
2016-03-04 |
2022-10-01 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
TWI742054B
(zh)
*
|
2016-03-08 |
2021-10-11 |
美商健生生物科技公司 |
Gitr抗體,方法及用途
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
US10894823B2
(en)
|
2016-03-24 |
2021-01-19 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
DK3433257T3
(da)
|
2016-03-24 |
2024-01-02 |
Novartis Ag |
Alkynylnukleosidanaloger som hæmmere af human rhinovirus
|
JP2019516681A
(ja)
|
2016-05-04 |
2019-06-20 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
|
WO2017192844A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
JP2019516687A
(ja)
|
2016-05-04 |
2019-06-20 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
|
CN109414420A
(zh)
|
2016-05-04 |
2019-03-01 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
EP3452450A1
(en)
|
2016-05-04 |
2019-03-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
TWI786044B
(zh)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
WO2017201502A1
(en)
|
2016-05-20 |
2017-11-23 |
Biohaven Pharmaceutical Holding Company Ltd. |
Use of glutamate modulating agents with immunotherapies to treat cancer
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
US10738126B2
(en)
|
2016-06-10 |
2020-08-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-GITR antibodies and uses thereof
|
DK3468957T3
(da)
|
2016-06-14 |
2020-09-14 |
Novartis Ag |
Krystallinsk form af (r)-4-(5-(cyclopro pylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamid som et antibakterielt middel
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
WO2017220989A1
(en)
|
2016-06-20 |
2017-12-28 |
Kymab Limited |
Anti-pd-l1 and il-2 cytokines
|
US11147818B2
(en)
|
2016-06-24 |
2021-10-19 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2018005950A1
(en)
|
2016-07-01 |
2018-01-04 |
Five Prime Therapeutics, Inc. |
Combined anti tumor therapy with a gitr agonist and cpg
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
SG11201900026TA
(en)
|
2016-07-14 |
2019-01-30 |
Bristol Myers Squibb Co |
Antibodies against tim3 and uses thereof
|
CA3031542A1
(en)
|
2016-07-20 |
2018-01-25 |
University Of Utah Research Foundation |
Cd229 car t cells and methods of use thereof
|
US20190292179A1
(en)
|
2016-07-21 |
2019-09-26 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
IL296127A
(en)
*
|
2016-07-22 |
2022-11-01 |
Dana Farber Cancer Inst Inc |
Antibodies to the glucocorticoid-induced tumor necrosis factor receptor and methods of using them
|
CN116271014A
(zh)
|
2016-08-05 |
2023-06-23 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
SG11201900746RA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
SG11201900744SA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
KR20190040990A
(ko)
|
2016-08-26 |
2019-04-19 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
WO2018047109A1
(en)
|
2016-09-09 |
2018-03-15 |
Novartis Ag |
Polycyclic pyridone compounds as antivirals
|
AU2017332161A1
(en)
|
2016-09-21 |
2019-04-04 |
The United States Government As Represented By The Department Of Veterans Affairs |
Chimeric antigen receptor (car) that targets chemokine receptor CCR4 and its use
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
EA037973B1
(ru)
*
|
2016-10-12 |
2021-06-18 |
Янссен Байотек, Инк. |
Антитела к gitr, способы и применение
|
TW201819380A
(zh)
|
2016-10-18 |
2018-06-01 |
瑞士商諾華公司 |
作為抗病毒劑之稠合四環吡啶酮化合物
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
US10660909B2
(en)
|
2016-11-17 |
2020-05-26 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
US20200078400A1
(en)
|
2016-12-03 |
2020-03-12 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
ES2894255T3
(es)
|
2016-12-22 |
2022-02-14 |
Amgen Inc |
Derivados de benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibidores de KRAS G12C para tratar el cáncer de pulmón, pancreático o colorrectal
|
EA201991204A1
(ru)
|
2016-12-22 |
2019-12-30 |
Университа Дельи Студи Манья Греча Катандзаро |
Моноклональное антитело против уникального сиалогликозилированного опухолеассоциированного эпитопа cd43
|
CN109071656B
(zh)
|
2017-01-05 |
2021-05-18 |
璟尚生物制药公司 |
检查点调节物拮抗剂
|
US10961239B2
(en)
|
2017-01-05 |
2021-03-30 |
Bristol-Myers Squibb Company |
TGF beta receptor antagonists
|
KR20190104048A
(ko)
|
2017-01-06 |
2019-09-05 |
이오반스 바이오테라퓨틱스, 인크. |
종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
|
EP3570844B1
(en)
|
2017-01-20 |
2023-09-06 |
Arcus Biosciences, Inc. |
Azolopyrimidine for the treatment of cancer-related disorders
|
WO2018138521A1
(en)
|
2017-01-27 |
2018-08-02 |
Ultrahuman One Limited |
Binding agents
|
AU2018218324A1
(en)
|
2017-02-10 |
2019-08-22 |
Eutilex Co., Ltd. |
IFN-γ-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibody and uses thereof
|
CA3054289A1
(en)
|
2017-02-21 |
2018-08-30 |
Regeneron Pharmaceuticals, Inc. |
Anti-pd-1 antibodies for treatment of lung cancer
|
EP3589657A1
(en)
*
|
2017-03-03 |
2020-01-08 |
Rinat Neuroscience Corp. |
Anti-gitr antibodies and methods of use thereof
|
SG10202110594UA
(en)
|
2017-03-31 |
2021-11-29 |
Bristol Myers Squibb Co |
Methods of treating tumor
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
KR20200020662A
(ko)
|
2017-04-03 |
2020-02-26 |
온콜로지, 인크. |
면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
WO2018193102A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
WO2018193104A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-cd25 antibody-drug conjugate
|
US10570138B2
(en)
|
2017-04-21 |
2020-02-25 |
Kyn Therapeutics |
Indole AHR inhibitors and uses thereof
|
EP3615070A1
(en)
|
2017-04-26 |
2020-03-04 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
KR20190139216A
(ko)
|
2017-04-28 |
2019-12-17 |
파이브 프라임 테라퓨틱스, 인크. |
Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
SG11201909955XA
(en)
|
2017-05-02 |
2019-11-28 |
Merck Sharp & Dohme |
Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
EA039583B1
(ru)
*
|
2017-05-02 |
2022-02-14 |
Регенерон Фармасьютикалз, Инк. |
Антитела против gitr и их применения
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
UY37718A
(es)
|
2017-05-05 |
2018-11-30 |
Novartis Ag |
2-quinolinonas triciclicas como agentes antibacteriales
|
US10543271B2
(en)
|
2017-05-12 |
2020-01-28 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
WO2018209049A1
(en)
|
2017-05-12 |
2018-11-15 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
EP3625260A1
(en)
|
2017-05-16 |
2020-03-25 |
Bristol-Myers Squibb Company |
Treatment of cancer with anti-gitr agonist antibodies
|
JP7189155B2
(ja)
|
2017-05-17 |
2022-12-13 |
アーカス バイオサイエンシズ インコーポレイティド |
癌関連障害の治療のためのキナゾリン-ピラゾール誘導体
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
CN116333129A
(zh)
|
2017-05-25 |
2023-06-27 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
EP3630839A1
(en)
|
2017-06-01 |
2020-04-08 |
Xencor, Inc. |
Bispecific antibodies that bind cd 123 cd3
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
JP2020522489A
(ja)
|
2017-06-02 |
2020-07-30 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いる処置のための製造物品および方法
|
WO2018226336A1
(en)
|
2017-06-09 |
2018-12-13 |
Providence Health & Services - Oregon |
Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer
|
UA127900C2
(uk)
|
2017-06-14 |
2024-02-07 |
Ейдісі Терапьютікс Са |
Схема дозування для введення adc до cd19
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
CN109136275B
(zh)
|
2017-06-19 |
2021-03-16 |
百奥赛图(北京)医药科技股份有限公司 |
人源化gitr基因改造动物模型的制备方法及应用
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
|
KR20200019865A
(ko)
|
2017-06-22 |
2020-02-25 |
노파르티스 아게 |
암 치료에 사용하기 위한 il-1베타 결합 항체
|
WO2018237157A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
WO2019006007A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
|
AU2018291032A1
(en)
|
2017-06-29 |
2020-01-16 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
CN111093651B
(zh)
|
2017-06-30 |
2023-06-06 |
百时美施贵宝公司 |
Ido抑制剂的无定形和结晶形式
|
CN110461874B
(zh)
*
|
2017-06-30 |
2022-04-12 |
江苏恒瑞医药股份有限公司 |
抗gitr抗体、其抗原结合片段及其医药用途
|
CA3070095A1
(en)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
WO2019023459A1
(en)
|
2017-07-28 |
2019-01-31 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
KR20200051646A
(ko)
|
2017-08-17 |
2020-05-13 |
이케나 온콜로지, 인코포레이티드 |
Ahr 억제제 및 이의 용도
|
US11306144B2
(en)
|
2017-08-25 |
2022-04-19 |
Five Prime Therapeutics, Inc. |
B7-H4 antibodies and methods of use thereof
|
JP7209697B2
(ja)
|
2017-08-31 |
2023-01-20 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
JP7208225B2
(ja)
|
2017-08-31 |
2023-01-18 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
JP7316263B2
(ja)
|
2017-08-31 |
2023-07-27 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
EP3684365A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND USES OF SUCH
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
WO2019074822A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
WO2019074824A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
CN111344297B
(zh)
|
2017-10-10 |
2023-10-20 |
百时美施贵宝公司 |
作为抗癌剂的环二核苷酸
|
US20200239577A1
(en)
|
2017-10-15 |
2020-07-30 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
EP3697801A1
(en)
|
2017-10-16 |
2020-08-26 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
RU2020116579A
(ru)
|
2017-10-25 |
2021-11-25 |
Новартис Аг |
Способы получения клеток, экспрессирующих химерный антигенный рецептор
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
US20210132042A1
(en)
|
2017-11-01 |
2021-05-06 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
KR20200116077A
(ko)
|
2017-11-01 |
2020-10-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
|
EP3703688A2
(en)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
EP3707138B1
(en)
|
2017-11-06 |
2022-07-13 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
AU2018368731A1
(en)
|
2017-11-16 |
2020-05-14 |
Novartis Ag |
Combination therapies
|
US20210079015A1
(en)
|
2017-11-17 |
2021-03-18 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
MA51184A
(fr)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics Inc |
Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
|
EP3728266A1
(en)
|
2017-12-20 |
2020-10-28 |
Novartis AG |
Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
|
MX2020006812A
(es)
|
2017-12-26 |
2020-11-06 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
KR20200103761A
(ko)
|
2017-12-27 |
2020-09-02 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd40 항체 및 그의 용도
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2019140229A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND THEIR USES
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
KR20200115620A
(ko)
|
2018-01-29 |
2020-10-07 |
메르크 파텐트 게엠베하 |
Gcn2 억제제 및 이의 용도
|
KR20200116481A
(ko)
|
2018-01-29 |
2020-10-12 |
메르크 파텐트 게엠베하 |
Gcn2 억제제 및 이의 용도
|
WO2019160829A1
(en)
|
2018-02-13 |
2019-08-22 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
WO2019165315A1
(en)
|
2018-02-23 |
2019-08-29 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists alone or in combination
|
WO2019166951A1
(en)
|
2018-02-28 |
2019-09-06 |
Novartis Ag |
Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
|
JP2021516051A
(ja)
|
2018-03-02 |
2021-07-01 |
ファイブ プライム セラピューティクス, インコーポレイテッド |
B7−h4抗体及びその使用方法
|
US11945834B2
(en)
|
2018-03-08 |
2024-04-02 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
CA3092589A1
(en)
|
2018-03-21 |
2019-09-26 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic ph
|
WO2019183551A1
(en)
|
2018-03-23 |
2019-09-26 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
CN110357958A
(zh)
*
|
2018-03-26 |
2019-10-22 |
信达生物制药(苏州)有限公司 |
抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)的小型化抗体、其聚合物及应用
|
CN110305210B
(zh)
|
2018-03-27 |
2023-02-28 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
US20210024873A1
(en)
|
2018-03-27 |
2021-01-28 |
Bristol-Myers Squibb Company |
Real-time monitoring of protein concentration using ultraviolet signal
|
EP3774911A1
(en)
|
2018-03-30 |
2021-02-17 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
EP3781162A1
(en)
|
2018-04-16 |
2021-02-24 |
Arrys Therapeutics, Inc. |
Ep4 inhibitors and use thereof
|
CN110386981A
(zh)
*
|
2018-04-20 |
2019-10-29 |
信达生物制药(苏州)有限公司 |
抗gitr抗体及其用途
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
WO2019213340A1
(en)
|
2018-05-03 |
2019-11-07 |
Bristol-Myers Squibb Company |
Uracil derivatives as mer-axl inhibitors
|
WO2019213516A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3788053A1
(en)
|
2018-05-04 |
2021-03-10 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
MA52564A
(fr)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
WO2019224275A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
CA3102256A1
(en)
|
2018-06-01 |
2019-12-05 |
Novartis Ag |
Dosing of a bispecific antibody that bind cd123 and cd3
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
AU2019284472A1
(en)
|
2018-06-11 |
2020-11-26 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
EP3807276A2
(en)
|
2018-06-12 |
2021-04-21 |
Amgen Inc. |
Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
US20210251994A1
(en)
|
2018-06-15 |
2021-08-19 |
Flagship Pioneering Innovations V, Inc. |
Increasing immune activity through modulation of postcellular signaling factors
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
DK3814348T3
(da)
|
2018-06-27 |
2023-10-30 |
Bristol Myers Squibb Co |
Substituerede naphthyridinonforbindelser, der er anvendelige som t-celleaktivatorer
|
EA202190137A1
(ru)
|
2018-06-27 |
2021-05-17 |
Бристол-Маерс Сквибб Компани |
Нафтиридиноновые соединения для применения в качестве активаторов t-клеток
|
EP3813880A4
(en)
|
2018-06-29 |
2022-07-13 |
Gensun Biopharma Inc. |
ANTITUMORS IMMUNOTEST POINT REGULATOR ANTAGONISTS
|
EP3817748A4
(en)
|
2018-07-06 |
2022-08-24 |
Kymera Therapeutics, Inc. |
TRICYCLIC CRBN LIGANDS AND USES THEREOF
|
EP3820904A2
(en)
|
2018-07-09 |
2021-05-19 |
Five Prime Therapeutics, Inc. |
Antibodies binding to ilt4
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
KR20210031722A
(ko)
|
2018-07-11 |
2021-03-22 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
US20210355113A1
(en)
|
2018-07-23 |
2021-11-18 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2020023355A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
US20210161898A1
(en)
|
2018-07-27 |
2021-06-03 |
Arcus Biosciences, Inc. |
Pyridone a2r antagonists
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US20210171909A1
(en)
|
2018-08-31 |
2021-06-10 |
Novartis Ag |
Methods of making chimeric antigen receptor?expressing cells
|
BR112021003305A2
(pt)
|
2018-08-31 |
2021-05-25 |
Novartis Ag |
métodos para produzir células que expressam receptor de antígeno quimérico
|
WO2020051424A1
(en)
|
2018-09-07 |
2020-03-12 |
Pic Therapeutics |
Eif4e inhibitors and uses thereof
|
BR112021004287A2
(pt)
|
2018-09-07 |
2021-08-03 |
Pfizer Inc. |
anticorpos anti-avss8 e composições e usos dos mesmos
|
CA3112326A1
(en)
|
2018-09-12 |
2020-03-19 |
Novartis Ag |
Antiviral pyridopyrazinedione compounds
|
JP7425049B2
(ja)
|
2018-09-25 |
2024-01-30 |
ハープーン セラピューティクス,インク. |
Dll3結合タンパク質および使用方法
|
EP3856779A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd22 chimeric antigen receptor (car) therapies
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
WO2020065453A1
(en)
|
2018-09-29 |
2020-04-02 |
Novartis Ag |
Process of manufacture of a compound for inhibiting the activity of shp2
|
WO2020077257A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
EP3873937A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
JP2022512917A
(ja)
|
2018-11-01 |
2022-02-07 |
ジュノー セラピューティクス インコーポレイテッド |
B細胞成熟抗原に特異的なキメラ抗原受容体を使用する処置方法
|
MX2021005734A
(es)
|
2018-11-16 |
2021-09-10 |
Juno Therapeutics Inc |
Metodos de dosificacion de celulas t modificadas para el tratamiento de malignidades de celulas b.
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
TW202033555A
(zh)
|
2018-11-16 |
2020-09-16 |
美商必治妥美雅史谷比公司 |
抗nkg2a抗體及其用途
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
EP3883565A1
(en)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
WO2020112781A1
(en)
|
2018-11-28 |
2020-06-04 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
WO2020113194A2
(en)
|
2018-11-30 |
2020-06-04 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
SG11202105424PA
(en)
|
2018-11-30 |
2021-06-29 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
BR112021011874A2
(pt)
|
2018-12-20 |
2021-09-08 |
Novartis Ag |
Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
|
WO2020132651A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
JP2022513971A
(ja)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
JP7407196B2
(ja)
|
2018-12-20 |
2023-12-28 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
AU2019404576A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
BR112021011351A2
(pt)
|
2018-12-21 |
2021-11-16 |
Novartis Ag |
Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica
|
WO2020128613A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1beta binding antibodies
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
JP2022514087A
(ja)
|
2018-12-21 |
2022-02-09 |
ノバルティス アーゲー |
IL-1β結合抗体の使用
|
EP3917570A1
(en)
|
2019-01-29 |
2021-12-08 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
KR20210129672A
(ko)
|
2019-02-15 |
2021-10-28 |
노파르티스 아게 |
치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
|
MX2021009763A
(es)
|
2019-02-15 |
2021-09-08 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
|
WO2020172658A1
(en)
|
2019-02-24 |
2020-08-27 |
Bristol-Myers Squibb Company |
Methods of isolating a protein
|
SG11202109422WA
(en)
|
2019-03-01 |
2021-09-29 |
Revolution Medicines Inc |
Bicyclic heterocyclyl compounds and uses thereof
|
US20230148450A9
(en)
|
2019-03-01 |
2023-05-11 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
WO2020187998A1
(en)
|
2019-03-19 |
2020-09-24 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
|
JP2022521355A
(ja)
|
2019-03-29 |
2022-04-06 |
ミスト セラピューティクス リミテッド ライアビリティ カンパニー |
T細胞治療薬を生成するためのエクスビボ方法ならびに関連する組成物および方法
|
JP2022528887A
(ja)
|
2019-04-02 |
2022-06-16 |
バイスクルテクス・リミテッド |
バイシクルトキシンコンジュゲートおよびその使用
|
EP3946360A4
(en)
|
2019-04-05 |
2023-05-10 |
Kymera Therapeutics, Inc. |
STAT DEGRADING AGENTS AND THEIR USES
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
RU2734432C1
(ru)
*
|
2019-04-23 |
2020-10-16 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с GITR
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
MA55805A
(fr)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V Inc |
Métodes de modulation de l'activité immunitaire
|
WO2020231766A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
WO2020231713A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
AU2020280024A1
(en)
|
2019-05-21 |
2021-12-09 |
Amgen Inc. |
Solid state forms
|
EP3973274A1
(en)
|
2019-05-23 |
2022-03-30 |
Bristol-Myers Squibb Company |
Methods of monitoring cell culture media
|
CN114174538A
(zh)
|
2019-05-30 |
2022-03-11 |
百时美施贵宝公司 |
适合于免疫肿瘤学疗法的多肿瘤基因特征
|
JP2022534981A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル-マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよび組み合わせ治療
|
WO2020243568A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
CA3141826A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2020263312A1
(en)
|
2019-06-28 |
2020-12-30 |
Gensun Biopharma, Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
EP4007756A1
(en)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Kif18a inhibitors
|
AU2020326627A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
KIF18A inhibitors
|
WO2021026179A1
(en)
|
2019-08-06 |
2021-02-11 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
US20230192860A1
(en)
|
2019-09-19 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies Binding to Vista at Acidic pH
|
JP7417715B2
(ja)
|
2019-09-26 |
2024-01-18 |
ノバルティス アーゲー |
抗ウイルスピラゾロピリジノン化合物
|
TW202128166A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
組合療法
|
EP4048285A1
(en)
|
2019-10-21 |
2022-08-31 |
Novartis AG |
Tim-3 inhibitors and uses thereof
|
CA3155857A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER
|
JP2022553858A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
BR112022008534A2
(pt)
|
2019-11-04 |
2022-08-09 |
Revolution Medicines Inc |
Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras
|
AU2020377925A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN116425742A
(zh)
|
2019-11-08 |
2023-07-14 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
EP4058432A1
(en)
|
2019-11-14 |
2022-09-21 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
AR120457A1
(es)
|
2019-11-14 |
2022-02-16 |
Amgen Inc |
Síntesis mejorada del compuesto inhibidor de g12c de kras
|
AU2020387392A1
(en)
|
2019-11-19 |
2022-07-14 |
Bristol-Myers Squibb Company |
Compounds useful as inhibitors of Helios protein
|
AU2020393912A1
(en)
|
2019-11-26 |
2022-06-09 |
Novartis Ag |
Chimeric antigen receptors binding BCMA and CD19 and uses thereof
|
CA3162892A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
AU2020394424A1
(en)
|
2019-11-26 |
2022-06-16 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
CN115151306A
(zh)
|
2019-11-26 |
2022-10-04 |
百时美施贵宝公司 |
(r)-n-(4-氯苯基)-2-((1s,4s)-4-(6-氟喹啉-4-基)环己基)丙酰胺的盐/共晶
|
JP2023505100A
(ja)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
共有ras阻害剤及びその使用
|
JP2023504042A
(ja)
|
2019-11-27 |
2023-02-01 |
ミスト セラピューティクス リミテッド ライアビリティ カンパニー |
調節物質を使用した腫瘍反応性t細胞組成物の生成方法
|
GB201917254D0
(en)
|
2019-11-27 |
2020-01-08 |
Adc Therapeutics Sa |
Combination therapy
|
EP4076520A4
(en)
|
2019-12-17 |
2024-03-27 |
Kymera Therapeutics Inc |
IRAQ DEGRADERS AND USES THEREOF
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
JP2023509359A
(ja)
|
2019-12-17 |
2023-03-08 |
フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド |
鉄依存性細胞分解の誘導物質との併用抗癌療法
|
CA3165399A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
IL294270A
(en)
|
2019-12-23 |
2022-08-01 |
Bristol Myers Squibb Co |
Substituted piperazine derivatives are useful as t-cell activators
|
JP2023507847A
(ja)
|
2019-12-23 |
2023-02-27 |
ブリストル-マイヤーズ スクイブ カンパニー |
T細胞アクティベーターとして有用な置換キナゾリニル化合物
|
WO2021133920A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
CN114846015A
(zh)
|
2019-12-23 |
2022-08-02 |
百时美施贵宝公司 |
用作t细胞激活剂的经取代的杂芳基化合物
|
US20230061608A1
(en)
|
2019-12-23 |
2023-03-02 |
Bristol-Myers Squibb Company |
Substituted quinolinonyl piperazine compounds useful as t cell activators
|
EP4087874A1
(en)
|
2020-01-06 |
2022-11-16 |
HiFiBiO (HK) Limited |
Anti-tnfr2 antibody and uses thereof
|
CN114929279A
(zh)
|
2020-01-07 |
2022-08-19 |
锐新医药公司 |
Shp2抑制剂给药和治疗癌症的方法
|
CA3163988A1
(en)
|
2020-01-07 |
2021-07-15 |
Germain MARGALL DUCOS |
Anti-galectin-9 antibody and uses thereof
|
BR112022012310A2
(pt)
|
2020-01-17 |
2022-09-06 |
Novartis Ag |
Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
|
WO2021163618A1
(en)
|
2020-02-14 |
2021-08-19 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
JP2023515211A
(ja)
|
2020-02-27 |
2023-04-12 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
JP2023516636A
(ja)
|
2020-02-27 |
2023-04-20 |
ミスト セラピューティクス リミテッド ライアビリティ カンパニー |
腫瘍反応性t細胞のエクスビボ富化および増大のための方法ならびに関連するその組成物
|
TW202146452A
(zh)
|
2020-02-28 |
2021-12-16 |
瑞士商諾華公司 |
結合cd123和cd3之雙特異性抗體的給藥
|
US11753403B2
(en)
|
2020-03-03 |
2023-09-12 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
JP2023506593A
(ja)
|
2020-03-06 |
2023-02-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗gitr抗体およびその使用
|
US20230140384A1
(en)
|
2020-03-09 |
2023-05-04 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
AU2021240046A1
(en)
|
2020-03-19 |
2022-09-29 |
Kymera Therapeutics, Inc. |
MDM2 degraders and uses thereof
|
WO2021188769A1
(en)
|
2020-03-19 |
2021-09-23 |
Arcus Biosciences, Inc. |
Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
WO2021207689A2
(en)
|
2020-04-10 |
2021-10-14 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
IL298111A
(en)
|
2020-06-02 |
2023-01-01 |
Arcus Biosciences Inc |
Antibodies to tigit
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
IL298473A
(en)
|
2020-06-11 |
2023-01-01 |
Novartis Ag |
zbtb32 inhibitors and uses thereof
|
MX2022016355A
(es)
|
2020-06-18 |
2023-04-03 |
Revolution Medicines Inc |
Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
BR112022026202A2
(pt)
|
2020-06-23 |
2023-01-17 |
Novartis Ag |
Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
|
JP2023532339A
(ja)
|
2020-06-29 |
2023-07-27 |
フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド |
サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
|
WO2022027058A1
(en)
|
2020-07-30 |
2022-02-03 |
Kymera Therapeutics, Inc. |
Methods of treating mutant lymphomas
|
CN116134027A
(zh)
|
2020-08-03 |
2023-05-16 |
诺华股份有限公司 |
杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
KR20230077722A
(ko)
|
2020-08-10 |
2023-06-01 |
지브이20 테라퓨틱스 엘엘씨 |
Igsf8을 표적화하여 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
|
CA3186504A1
(en)
|
2020-08-17 |
2022-02-24 |
Stephen J. Blakemore |
Bicycle conjugates specific for nectin-4 and uses thereof
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022047412A1
(en)
|
2020-08-31 |
2022-03-03 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
AU2021344830A1
(en)
|
2020-09-03 |
2023-04-06 |
Revolution Medicines, Inc. |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
WO2022060836A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Indole derivatives as ras inhibitors in the treatment of cancer
|
US20230374064A1
(en)
|
2020-10-05 |
2023-11-23 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
MX2023005609A
(es)
|
2020-11-13 |
2023-05-29 |
Novartis Ag |
Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
|
CN116490607A
(zh)
|
2020-11-25 |
2023-07-25 |
上海君赛生物科技有限公司 |
肿瘤浸润淋巴细胞培养基及其应用
|
EP4252754A1
(en)
|
2020-11-25 |
2023-10-04 |
Shanghai Juncell Therapeutics Co., Ltd. |
Pharmaceutical composition for enhancing cell killing, and use thereof
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
CA3204091A1
(en)
|
2020-12-08 |
2022-06-16 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
US20220233689A1
(en)
|
2020-12-28 |
2022-07-28 |
Bristol-Myers Squibb Company |
Methods of treating tumors
|
AU2021411486A1
(en)
|
2020-12-28 |
2023-06-29 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
WO2022148279A1
(zh)
*
|
2021-01-08 |
2022-07-14 |
苏州丁孚靶点生物技术有限公司 |
药物产品及其用途
|
CA3204630A1
(en)
|
2021-01-11 |
2022-07-14 |
Nicholas Keen |
Methods for treating cancer
|
US20230113202A1
(en)
|
2021-02-02 |
2023-04-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
TW202246334A
(zh)
|
2021-02-02 |
2022-12-01 |
美商美國禮來大藥廠 |
Gitr拮抗劑及其使用方法
|
KR20230152692A
(ko)
|
2021-02-02 |
2023-11-03 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
WO2022169921A1
(en)
|
2021-02-04 |
2022-08-11 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
KR20230146052A
(ko)
|
2021-02-12 |
2023-10-18 |
에프. 호프만-라 로슈 아게 |
암 치료용 비시클릭 테트라히드로아제핀 유도체
|
KR20230145446A
(ko)
|
2021-02-15 |
2023-10-17 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak4 분해제 및 이의 용도
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
EP4305041A1
(en)
|
2021-03-08 |
2024-01-17 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
KR20230165276A
(ko)
|
2021-03-31 |
2023-12-05 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
WO2022216573A1
(en)
|
2021-04-05 |
2022-10-13 |
Bristol-Myers Squibb Company |
Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
|
IL307343A
(en)
|
2021-04-06 |
2023-11-01 |
Bristol Myers Squibb Co |
Pyridinyl substituted oxisoisoindoline compounds
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
CA3215081A1
(en)
|
2021-04-16 |
2022-10-20 |
Alfredo C. Castro |
Mek inhibitors and uses thereof
|
PE20240089A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cancer
|
KR20240004960A
(ko)
|
2021-05-05 |
2024-01-11 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
EP4334324A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
WO2022240161A1
(ko)
*
|
2021-05-10 |
2022-11-17 |
메디맵바이오 주식회사 |
항-gitr 항체 및 이의 용도
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
CN117295741A
(zh)
|
2021-05-21 |
2023-12-26 |
艾库斯生物科学有限公司 |
Axl化合物
|
WO2022246179A1
(en)
|
2021-05-21 |
2022-11-24 |
Arcus Biosciences, Inc. |
Axl inhibitor compounds
|
WO2022254337A1
(en)
|
2021-06-01 |
2022-12-08 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
CA3218590A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
AU2022303363A1
(en)
|
2021-06-29 |
2024-01-18 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
EIF4E inhibitors and their uses
|
WO2023039089A1
(en)
|
2021-09-08 |
2023-03-16 |
Twentyeight-Seven, Inc. |
Papd5 and/or papd7 inhibiting 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
TW202325279A
(zh)
|
2021-10-29 |
2023-07-01 |
美商阿克思生物科學有限公司 |
HIF-2α抑制劑及其使用方法
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
WO2023150186A1
(en)
|
2022-02-01 |
2023-08-10 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023154905A1
(en)
|
2022-02-14 |
2023-08-17 |
Gilead Sciences, Inc. |
Antiviral pyrazolopyridinone compounds
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023173011A1
(en)
|
2022-03-09 |
2023-09-14 |
Bristol-Myers Squibb Company |
Transient expression of therapeutic proteins
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023175614A1
(en)
|
2022-03-15 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023215719A1
(en)
|
2022-05-02 |
2023-11-09 |
Arcus Biosciences, Inc. |
Anti-tigit antibodies and uses of the same
|
WO2023215560A1
(en)
|
2022-05-05 |
2023-11-09 |
Atoosa Corporation |
Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
|
WO2023230205A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024015251A1
(en)
|
2022-07-15 |
2024-01-18 |
Arcus Biosciences, Inc. |
Inhibitors of hpk1 and methods of use thereof
|
WO2024020034A1
(en)
|
2022-07-20 |
2024-01-25 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024031091A2
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
WO2024036100A1
(en)
|
2022-08-08 |
2024-02-15 |
Bristol-Myers Squibb Company |
Substituted tetrazolyl compounds useful as t cell activators
|
WO2024036101A1
(en)
|
2022-08-09 |
2024-02-15 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024059142A1
(en)
|
2022-09-14 |
2024-03-21 |
Arcus Biosciences, Inc. |
Dispersions of etrumadenant
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024081385A1
(en)
|
2022-10-14 |
2024-04-18 |
Arcus Biosciences, Inc. |
Hpk1 inhibitors and methods of use thereof
|